# Neumora Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neumora-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.neumoratx.com/
- Total disclosed funding: $612M
- Latest round: Series B (Oct 11, 2022)
- Investors on record: 17

## About

Neumora Therapeutics, Inc. is a US-based biopharmaceutical company focused on developing innovative therapeutics for neuropsychiatric and neurodegenerative disorders through precision medicine.Founded in 2019 in Watertown, US, Neumora Therapeutics specializes in the development of therapeutics addressing brain diseases. The company’s leadership includes CEO Henry Gosebruch. In September 2023, Neumora completed an IPO, raising USD 250 mn, marking a significant milestone in its funding history.Neumora's core offerings include innovative therapeutics designed for brain diseases, utilizing a precision medicine approach to target biological pathways in the Central Nervous System (CNS). The company’s pipeline addresses unmet needs in brain disease treatment, serving healthcare providers, pharmaceutical partners, and the global population affected by brain disorders.Neumora focuses its revenue generation on strategic partnerships and collaborations, entering licensing and co-development agreements to facilitate commercializing its therapeutic products. Revenue is structured around milestone payments tied to drug development and regulatory approvals, alongside royalties from product sales once they reach the market.Following its IPO on September 14, 2023, which raised USD 250 mn, Neumora plans to accelerate the development of its precision neuroscience platform and its pipeline for neuropsychiatric and neurodegenerative disorders. The funding will support the launch of upcoming products and expansion into new markets, with aims to enhance its presence across North America, Europe, and selected Asian markets.

## Funding rounds

- Series B, Oct 11, 2022, $112M — ARCH Venture Partners, Polaris Partners, Amgen Ventures, Invus [DUP], F-Prime Capital, Altitude Life Science Ventures, Mubadala Capital, Newpath Partners, Abu Dhabi Growth Fund, Exor Ventures
- Series A, Oct 7, 2021, $500M — ARCH Venture Partners, Polaris Partners, Alexandria Venture Investments, Amgen Ventures, Invus [DUP], F-Prime Capital, Altitude Life Science Ventures, Surveyor Capital, Waycross Ventures, SB Investment Advisers, Mubadala Capital, Newpath Partners, Logos Capital, Catalio Capital Management, re.Mind Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- Invus [DUP] — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series A, Series B
- Surveyor Capital — Series A
- Waycross Ventures — Series A
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series A
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A, Series B
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A, Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- re.Mind Capital (https://capitalatlas.ai/funds/re-mind-capital) — Series A
- Abu Dhabi Growth Fund — Series B
- Exor Ventures — Series B